FishmanJ.A., RubinR.H.Infection in organ-transplant recipients. N Engl J Med1998; 338: 1741–51.
2.
DharnidharkaV.R., StableinD.M., HarmonW.E.Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant2004; 4: 384–89.
3.
HirschH.H.BK virus: opportunity makes a pathogen. Clin Infect Dis2005; 41: 354–60.
4.
FischerS.A.Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation2008; 86: 1327–39.
5.
HumarA., MichaelsM.American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant2006; 6: 262.
6.
KottonC.N., KumarD., CaliendoA.M.. Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation2010; 89: 779–95.
7.
BaldantiF., GattiM., FurioneM.. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell depleted HIA-haploidentical stem cell transplantation. J Clin Microbiol2008; 46: 3672–77.
8.
NickeleitV., KlimkaitT., BinetI.F.. Testing for Polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med2000; 342: 1309–15.
9.
SmetsF., LatinneD., BazinH.. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation2002; 73: 1603–10.
10.
GinevriF., HirschH.H., ComoliP.Cellular immune responses to BK virus. Curr Opin Organ Transplant2008; 13: 569–74.
11.
RooneyC.M., SmithC.A., NgC.Y.. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet1995; 345: 9–12.
12.
ChoquetS., LeblondV., HerbrechtR.. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood2006; 107: 3053–57.
13.
PayaC., HumarA., DominguezE.. Valganciclovir Solid Organ Transplant Study Group Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant2004; 4: 611–20.
14.
HirschH.H., BrennanD.C., DrachenbergC.B.. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation2005; 79: 1277–86.
RamosE., DrachenbergC.B., PapadimitriouJ.C.. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol2002; 13: 2145–51.
17.
ScholdJ.D., RehmanS., KayleL.K., MaglioccaJ., SrinivasT.R., Meier-KriescheH.U.Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int2009; 22: 626–34.
FunkG.A., SteigerJ., HirschH.H.Rapid dynamics of Polyomavirus type BK in renal transplant recipients. J Infect Dis2006; 193: 80–7.
20.
RandhawaP.S., FinkelsteinS., ScantleburyV.. Human Polyoma virus-associated interstial nephritis in the allograft kidney. Transplantation1999; 67: 103.
21.
DrachenbergC.B., PapadimitriouJ.C., HirschH.H.. Histological patterns of Polyomavirus nephropathy: Correlation with graft outcome and viral load. Am J Transplantation2004; 4: 2082–92.
AcottP.D., HirschH.H.BK virus infection, replication, and diseases in pediatric kidney transplantation. Pediatr Nephrol2007; 22: 1243–50.
24.
KDIGO Guidelines. Am J Transplant2009; 9(Suppl 3): S44–58.
25.
HirschH.H., KnowlesW., DickenmannM.. Prospective study of Polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med2002; 347: 488–96.
26.
BrennanD.C., AghaI., BohlD.L.. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant2005; 5: 582–94.
27.
GinevriF., AzziA., HirschH.H.. Prospective monitoring of Polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant2007; 7: 2727–35.
28.
HirschHH, RandhawaP., AST Infectious Diseases Com-munity of Practice. BK virus in solid organ transplant recipients. Am J Transplant2009; 9(Suppl 4): S136–46.
29.
SaadE.R., BresnahanB.A., CohenE.P.. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation2008; 85: 850–4.
30.
GinevriF., De SantisR., ComoliP.. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation2003; 75: 1266–70.
31.
GreenM.Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant2001; 1: 103–8.
32.
OpelzG., DohlerB.Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant2003; 4: 222–30.
33.
MerloA., TurriniR., DolcettiR.. The interplay between EBV and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica2010; 95: 1769–77.
GrossT.G., SteinbuchM., DeForT.. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant1999; 23: 251–8.
36.
SwerdlowS.H., CampoE., HarrisN.L.. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th) 2008. Lyon, France: IARC Press.
37.
CohenJ.I.Epstein-Barr virus infection. N Engl J Med2000; 343: 481–92.
38.
NalesnikM., JaffeR., StarzlT.E.. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression. Am J Pathol1988; 133: 173–92.
39.
BaldantiF., GrossiP., FurioneM.. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol2000; 38: 613–9.
40.
YangJ., TaoQ., FlinnI.W.. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood2000; 96: 4055–63.
41.
ComoliP., MaccarioR., LocatelliF.. Treatment of EBV-related postrenal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant2005; 5: 1415–22.
42.
SavoieA., PerpeteC., CarpentierL., JoncasJ., AlfieriC.Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood1994; 83: 2715–22.
43.
RoweD.T., WebberS., SchauerE.M., ReyesJ., GreenM.Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis2001; 3: 79–87.
44.
LeeT.C., SavoldoB., RooneyC.M.. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant2005; 5: 2222–8.
45.
GinevriF., Di MarcoE., ParodiA.. EBV viral load monitoring and reduction of immunosuppression do not successfully prevent PTLD after pediatric kidney transplantation. Am J Transplant2008; 8(s2): 477.
46.
ComoliP., RooneyC.M.Treatment of Epstein-Barr virus infections. In: JensonH.B., TselisA. eds. Epstein-Barr virus, New York: Taylor & Francis, 2006; 351–72.
ChoquetS., LeblondV., HerbrechtR.. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood2006; 107: 3053–7.
49.
PerrineS.P., HermineO., SmallT.. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood2007; 109: 2571–8.
50.
GrossT.G., BucuvalasJ.C., ParkJ.R.. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol2005; 23: 6481–8.
51.
YangJ., LemasV.M., FlinnI.W., KroneC., AmbinderR.E.Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. Blood2000; 95: 241–8.
SavoldoB., RooneyC.M., Quiros-TejeiraR.E.. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant2005; 5: 566–72.
54.
MattesF.M., VargasA., KopycinskiJ.. Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High-Level Replication After Renal Transplantation. Am J Transplant2008; 8: 990–9.
55.
SesterU., PresserD., DirksJ., GartnerB.C., KohlerH., SesterM.PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant2008; 8: 1486–97.
56.
BinggeliS., EgliA., SchaubS.. Polyomavirus BK-specific cellular immune response to VP1 and Large T-antigen in kidney transplant recipients. Am J Transplant2007; 7: 1131–9.
57.
ProsserS.E., OrentasR.J., JurgensL., CohenE.P., HariharanS.Recovery of BK virus Large-T-antigen-specific cellular immune response correlates with resolution of BK virus nephropathy. Transplantation2008; 85: 185–92.
58.
ComoliP., LocatelliF., GinevriF., MaccarioR.Cellular immunotherapy for viral infections in solid organ transplant recipients. Curr Opin Organ Transplant2002; 7: 314–9.
